NCT07436858RecruitingPhase 1
Whole body HER2 quantification with 89Zr-Trastuzumab PET/CT to asses Zr-trastuzumab accumulation in HER2-mutated and HER2-overexpressing metastatic non-small cell lung cancer
Source: EU CTIS (euclinicaltrials.eu) · Last updated 30 Jul 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 24 Apr 2026
- Start date
- 2 Oct 2026
- Lead sponsor
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Diseases
- Lung cancer
- NCT number
- NCT07436858
- EU CT number
- 2026-525568-17-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 20
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Netherlands Cancer Institute Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.